5 results on '"Vundavalli V. Murty"'
Search Results
2. MLL/KMT2Atranslocations in diffuse large B-cell lymphomas
- Author
-
Vundavalli V. Murty, Bachir Alobeid, Tatyana Gindin, and Govind Bhagat
- Subjects
Cancer Research ,Myeloid ,biology ,Large cell ,Context (language use) ,Hematology ,General Medicine ,medicine.disease ,Leukemia ,KMT2A ,medicine.anatomical_structure ,Oncology ,immune system diseases ,hemic and lymphatic diseases ,Immunology ,medicine ,Cancer research ,biology.protein ,Splenic marginal zone lymphoma ,Diffuse large B-cell lymphoma ,Lymphoid leukemia - Abstract
Translocations of the histone-lysine N-methyltransferase 2A (KMT2A) gene, formerly known as myeloid lymphoid leukemia/mixed-lineage leukemia gene, are commonly associated with high-risk de novo or therapy-associated B-cell and T-cell lymphoblastic leukemias and myeloid neoplasms. Rare B-cell non-Hodgkin lymphomas harboring KMT2A translocations have been reported, but information regarding the clinical behavior of such cases is limited. Here, we describe two extranodal diffuse large B-cell lymphomas (DLBCLs): a primary thyroid DLBCL and a large cell transformation of a splenic marginal zone lymphoma, which displayed complex karyotypes and translocations involving chromosome 11q23 targeting the KMT2A gene. The pathological and clinical characteristics of these cases are discussed in the context of previously reported lymphomas associated with different types of KMT2A genetic aberrations. In contrast to the poor clinical outcomes of patients with acute leukemias and myeloid neoplasms associated with KMT2A translocations, patients with B-cell non-Hodgkin lymphomas, exhibiting similar translocations, appear to respond well to immunochemotherapy. Our findings add to the growing list of histone methyltransferase genes deregulated in DLBCL and highlight the diversity of mechanisms, altering the function of epigenetic modifier genes in lymphomas.
- Published
- 2014
- Full Text
- View/download PDF
3. Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia
- Author
-
Mark, Ewalt, Subhadra, Nandula, Adrienne, Phillips, Bachir, Alobeid, Vundavalli V, Murty, Mahesh M, Mansukhani, and Govind, Bhagat
- Subjects
Adult ,Male ,Proto-Oncogene Proteins B-raf ,Leukemia, Hairy Cell ,Lymphoma, B-Cell ,Reverse Transcriptase Polymerase Chain Reaction ,Lymphoma, Non-Hodgkin ,Middle Aged ,Prognosis ,Real-Time Polymerase Chain Reaction ,Young Adult ,Humans ,Point Mutation ,Female ,Microsatellite Instability ,RNA, Messenger ,Neoplasm Recurrence, Local ,Aged - Abstract
Hairy cell leukaemia (HCL) is a rare type of B-cell non-Hodgkin lymphoma (B-NHL), which is not known to be associated with any characteristic recurrent karyotypic abnormality. A recent study that used massively parallel whole exome sequencing identified an activating V600E mutation in BRAF, which appeared specific for HCL. Here, we confirm the specificity of BRAF V600E for HCL among low and intermediate grade B-NHL and describe a real-time polymerase chain reaction method for detecting this mutation in cases with low tumour burden. The V600E mutation does not appear to be associated with microsatellite instability, unlike the case in colorectal cancer. Thus, in conjunction with prior data, our results suggest incorporation of BRAF V600E mutation analysis in the diagnostic workup of HCL cases. Additionally, targeting the Ras-Raf-Mek-Erk-Map kinase pathway should be investigated as a potential therapeutic strategy for patients with this disease.
- Published
- 2011
4. KHSV(-) EBV(-) post-transplant effusion lymphoma with plasmablastic features: variant of primary effusion lymphoma?
- Author
-
Adriana I. Colovai, Deborah W. Sevilla, Mahesh M. Mansukhani, Bachir Alobeid, Darryl A. Oble, Ajai Chari, Jennifer S. Lambe, Govind Bhagat, Vundavalli V. Murty, and Subhadra V. Nandula
- Subjects
Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,viruses ,Isochromosome ,Plasma Cells ,Biology ,Chronic liver disease ,Virus ,Immunophenotyping ,immune system diseases ,hemic and lymphatic diseases ,Lymphoma, Primary Effusion ,medicine ,Humans ,Sarcoma, Kaposi ,virus diseases ,Hematology ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,Middle Aged ,medicine.disease ,Lymphoma ,Liver Transplantation ,Oncology ,Effusion ,Herpesvirus 8, Human ,Sarcoma ,Primary effusion lymphoma - Abstract
Primary effusion lymphoma (PEL) is a rare type of B-cell non-Hodgkin lymphoma (NHL), which predominantly occurs in HIV-infected individuals, and is pathogenetically linked with Kaposi sarcoma (KS)-associated herpes virus/human herpes virus-8 (KSHV/HHV-8) infection with or without evidence of Epstein-Barr virus (EBV) co-infection. Although uncommon, PELs have been reported in immunocompetent patients and recipients of solid organ allografts. Rare cases of KSHV(-) EBV(+) post-transplant effusion lymphomas resembling PEL have also been described, as have KSHV(-) EBV(-) effusion lymphomas, the latter including those arising in individuals with chronic liver disease. We report a unique KSHV(-) EBV(-) post-transplant effusion lymphoma associated with serum paraproteins, occurring in an HIV(-) individual, which had cytologic features and phenotype similar to PEL, and displayed a complex karyotype including isochromosome 12p and translocation t(8;22), resulting in rearrangement of c-MYC.
- Published
- 2009
5. MLL/KMT2A translocations in diffuse large B-cell lymphomas.
- Author
-
Gindin T, Murty V, Alobeid B, and Bhagat G
- Subjects
- Aged, Female, Humans, Lymphoma, Large B-Cell, Diffuse pathology, Male, Translocation, Genetic, Histone-Lysine N-Methyltransferase genetics, Histone-Lysine N-Methyltransferase metabolism, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse metabolism, Myeloid-Lymphoid Leukemia Protein genetics, Myeloid-Lymphoid Leukemia Protein metabolism
- Abstract
Translocations of the histone-lysine N-methyltransferase 2A (KMT2A) gene, formerly known as myeloid lymphoid leukemia/mixed-lineage leukemia gene, are commonly associated with high-risk de novo or therapy-associated B-cell and T-cell lymphoblastic leukemias and myeloid neoplasms. Rare B-cell non-Hodgkin lymphomas harboring KMT2A translocations have been reported, but information regarding the clinical behavior of such cases is limited. Here, we describe two extranodal diffuse large B-cell lymphomas (DLBCLs): a primary thyroid DLBCL and a large cell transformation of a splenic marginal zone lymphoma, which displayed complex karyotypes and translocations involving chromosome 11q23 targeting the KMT2A gene. The pathological and clinical characteristics of these cases are discussed in the context of previously reported lymphomas associated with different types of KMT2A genetic aberrations. In contrast to the poor clinical outcomes of patients with acute leukemias and myeloid neoplasms associated with KMT2A translocations, patients with B-cell non-Hodgkin lymphomas, exhibiting similar translocations, appear to respond well to immunochemotherapy. Our findings add to the growing list of histone methyltransferase genes deregulated in DLBCL and highlight the diversity of mechanisms, altering the function of epigenetic modifier genes in lymphomas., (Copyright © 2014 John Wiley & Sons, Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.